- Home
- ED vs LIVN Comparison
ED vs LIVN Comparison
Compare ED & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ED | LIVN |
|---|---|---|
| Founded | 1884 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 3.5B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | ED | LIVN |
|---|---|---|
| Price | $99.66 | $62.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $103.29 | $65.00 |
| AVG Volume (30 Days) | ★ 1.9M | 572.1K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | ★ 7.94 | N/A |
| EPS | ★ 5.74 | N/A |
| Revenue | ★ $16,593,000,000.00 | $1,348,962,000.00 |
| Revenue This Year | $11.45 | $12.25 |
| Revenue Next Year | $3.35 | $6.75 |
| P/E Ratio | $17.31 | ★ N/A |
| Revenue Growth | ★ 10.39 | 8.63 |
| 52 Week Low | $87.28 | $32.48 |
| 52 Week High | $114.87 | $65.57 |
Technical Indicators
Market Signals| Indicator | ED | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 54.92 |
| Support Level | $97.11 | $61.79 |
| Resistance Level | $100.33 | $63.69 |
| Average True Range (ATR) | 1.39 | 1.39 |
| MACD | 0.27 | -0.41 |
| Stochastic Oscillator | 87.16 | 12.16 |
Price Performance
Historical ComparisonAbout ED Consolidated Edison Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.